Aotai Biotech released its 2026 interim report. First-half net profit attributable to the parent was 50.84 million yuan, down 61.5% year on year. Operating revenue was 392 million yuan, down 8.8% year on year. Net profit attributable to the parent after deducting non-recurring items was 41.77 million yuan, down 61.8% year on year. Net operating cash flow was 52.89 million yuan, down 13.8% year on year. Earnings per share were 0.64 yuan. In the second quarter, operating revenue was 197 million yuan, down 11.1% year on year, and net profit attributable to the parent was 31.45 million yuan, down 55.6% year on year. As of the end of the second quarter, total assets were 3.997 billion yuan, down 5.8% from the end of the previous year, and net assets attributable to the parent were 3.761 billion yuan, down 4.7% from the end of the previous year. The company continued to invest in research and development, with R&D expenses accounting for 15.40% of operating revenue. It completed registration for nine new EU IVDR products, bringing cumulative IVDR certificates to 340, added nearly 300 new active business customers at home and abroad, and launched 104 new products.
Hangzhou Alltest Biotech Co. Ltd. AFirst-half net profit fell 61.5% year on year, with revenue down 8.8%.